In 2026, The Lancet formally announced that Polycystic Ovary Syndrome (PCOS) would be renamed PMOS — Polyendocrine Metabolic Ovarian Syndrome. This long-overdue change reflects a deeper scientific truth: PMOS is not just an ovarian condition. It is a whole-body endocrine and metabolic disorder affecting more than 170 million women worldwide.

For many women, this renaming marks a turning point — one that brings clarity, accuracy, and a new path toward proper care.

Why PCOS Was Renamed PMOS

The old name misled women.

The term "polycystic" made many women believe PMOS meant:

• "ovarian cysts that require surgery"
• "a fertility-only problem"
• "only overweight women get it"
• "it disappears after menopause"

But the truth is very different:

• The "cysts" are not cysts, but small follicles that failed to develop
• PMOS involves global hormonal and metabolic disruption, not just the ovaries
• 30% of cases occur in lean women
• Cardiometabolic risks—diabetes, cardiovascular disease—persist lifelong, even after menopause
• Up to 70% of women remain undiagnosed due to misleading terminology

An irregular menstrual cycle is not a minor inconvenience — it is a "whole-body health alarm".

What PMOS Really Means

The new name clarifies the root problem:

P — Polyendocrine

PMOS affects multiple hormonal systems:

• brain hormone centres
• pancreas
• adrenal glands
• ovaries

All show dysregulation, not just the ovaries.

M — Metabolic

Insulin resistance is the core mechanism, tightly linked to:

• obesity and abdominal fat
• elevated blood sugar
• fatty liver
• cholesterol imbalance
• cardiovascular risks

OS — Ovarian Syndrome

Ovarian dysfunction remains part of the picture, but the misleading term "polycystic" has been removed.

In simple terms:

PMOS is not an ovarian disease — it is a long-term systemic endocrine-metabolic condition requiring continuous care.

New Clinical Approach: From Fertility-Only to Whole-Body Management

Old approach:

'Regulate periods → stimulate ovulation → end of treatment.'

New recommended approach: multi-disciplinary medical tracking:

• blood glucose + insulin resistance
• full lipid panel
• sex hormones + AMH
• waist circumference + body fat percentage

Care teams should include gynecology + endocrinology + nutrition + psychological support.

How Humansa Supports Women with PMOS

Humansa's clinical philosophy aligns fully with the new global standards.

1. Comprehensive Metabolic & Hormonal Assessment

• blood glucose & insulin
• sex hormones
• body composition
• DEXA bone density screening
• NAD+ cellular energy testing

2. Personalised Lifestyle & Nutrition Interventions

Humansa designs bespoke nutrition and lifestyle plans, targeting the root cause — metabolic restoration rather than short-term symptomatic control.

3. Multi-Disciplinary Medical Team (MDT)

Humansa coordinates:

• Gynecology
• Endocrinology
• nutrition & health coaching
• psychological support

to manage PMOS holistically

4. Continuous Tracking Every 3–6 Months

PMOS isn't a one-time diagnosis. Humansa provides cyclical monitoring and dynamic adjustment of plans.

PMOS Naming Is the Beginning — Not the End

The renaming of PCOS to PMOS marks a global shift in recognising women's health needs with accuracy and respect. By focusing on endocrine balance, metabolic health and long-term prevention, women can finally receive care that addresses the root cause — not just the symptoms.

Humansa is committed to helping women understand their bodies, respond to the right signals and build long-term, sustainable wellbeing through its comprehensive Women's Health Management Program.

References

The Lancet Diabetes & Endocrinology (2026). Global Consensus Statement on Renaming PCOS to PMOS.

World Health Organization (WHO). Global Health Estimates: Endocrine and Metabolic Disorder Burden in Women.

Rotterdam ESHRE/ASRM Workshop Group. Revised diagnostic criteria for ovarian dysfunction and metabolic presentation.

Professor Helena Teede, Monash University. PCOS/PMOS research and international guideline leadership.

Professor Terhi Piltonen, University of Oulu. Endocrine–metabolic mechanisms in PMOS.

NIH / NICHD. Understanding insulin resistance in PCOS/PMOS.